Accessibility Menu
Forte Biosciences logo

Forte Biosciences(NASDAQ) FBRX

Market Cap$1.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-82%
5 Year-90%
1 Year+656%
1 Month+262%
$77.05
+0.68%
+0.52Today
Forte Biosciences last closing stock price
MetricPriceDate
Last closeUSD 76.982026-07-30
Forte Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+28.94%USD 59.702026-07-23
1 month+262.26%USD 21.252026-06-30
3 month+173.08%USD 28.192026-05-01
Year to date+182.29%USD 27.272025-12-31
1 year+655.82%USD 10.192025-07-30
3 year+204.87%USD 25.252023-07-31
5 year-89.72%USD 749.002021-07-30
Since inception-81.67%USD 420.002020-06-16

Forte Biosciences Financials at a Glance

Market Cap

$1.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$75.86M

EPS (TTM)

-$5.11

P/E Ratio

-15.07

Dividend

$0.00

Beta (Volatility)

0.83 (Low)

Price

$77.05

Volume

2,368,055.356

Open

$76.57

Previous Close

$76.98

Daily Range

$76.50 - $77.20

52-Week Range

$9.10 - $77.20

Estimated Earnings Date

Aug 13, 2026

FBRX News

Foolcom-Featured.png

Forte Biosciences Tops Q2 Loss Forecasts

Motley Fool Markets TeamAug 14, 2025
Scientists unhappy

Why Forte Biosciences Stock Is Imploding Today

Keith SpeightsSep 3, 2021

FBRX: Motley Fool Moneyball Superscore

45

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Forte Biosciences

Forte Biosciences develops medicines for people with autoimmune diseases. Its main drug candidate aims to help those with conditions like celiac disease and vitiligo. The company focuses on treatments that target the immune system’s overactivity.

What’s in the Medicine Cabinet?

  • FB102: Experimental antibody drug for autoimmune diseases, including celiac disease, vitiligo, and alopecia areata. No commercial sales or revenue yet.
  • Patent Portfolio: Pending and granted patents for FB102 and related uses, targeting future protection in major markets.
  • Outsourced Development: Uses third-party partners for manufacturing and clinical trials, allowing flexibility and lower fixed costs.

Growth Spurts and Strategic Moves

  • Launched Phase 2 trial for celiac disease in July 2025.
  • Started Phase 1b trials for vitiligo and alopecia areata in 2025.
  • Raised $75 million in a public offering in June 2025.
  • Secured $53 million in private placement in November 2024.
  • Received FDA approval for a new clinical trial in November 2025.

Why Forte’s Approach Stands Out

Forte’s single-drug focus allows deep specialization in autoimmune research. Outsourcing manufacturing and trials keeps operations lean and adaptable. Its patent strategy aims for long-term protection in key markets.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Net loss was $-18 million in Q3 2025, down 113% from Q3 2024.
  • Operating expenses reached $-18 million in Q3 2025, up 110.7% year-over-year.
  • Cash and equivalents totaled $77 million as of December 31, 2025.
  • R&D expenses rose 174.7% to $58.2 million in 2025.

Bottom Line

Forte is a focused biotech firm betting on one main drug for autoimmune diseases. Its future depends on clinical trial success and continued funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

22

CEO

Paul A. Wagner, PhD, CFA

Website

www.fortebiorx.com

Headquarters

Dallas, TX 75247, US

FBRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-106.16%

Return on Capital

-115.85%

Return on Assets

-112.84%

Earnings Yield

-6.64%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

20.48M

Volume

2.37M

Avg. Volume

964.77K

Financials (TTM)

Gross Profit

-$6.00K

Operating Income

-$76.97M

EBITDA

-$74.38M

Operating Cash Flow

-$59.34M

Capital Expenditure

-$55.00K

Free Cash Flow

-$59.39M

Cash & ST Invst.

$58.22M

Total Debt

$0.00

Forte Biosciences Performance Analysis

Forte Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Forte Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Forte Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -19.96-48.6%
20232023-12-31USD -24.9224.9%
20242024-12-31USD -12.17-51.2%
20252025-12-31USD -4.71-61.3%
Forte Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3029.9%
Q32025-09-30-3.1%
Q42025-12-31-40.4%
Q12026-03-3110.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$19.00K

-46.2%

Gross Margin

0.00%

N/A

Market Cap

$1.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$71.66M

N/A

Employees

22

N/A

Net Income

-$22.14M

-41.4%

EBITDA

-$21.74M

-39.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$58.22M

+27.0%

Total Debt

$0.00

N/A

Accounts Receivable

$655.00K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.13%

N/A

Return on Invested Capital

-1.77%

N/A

Free Cash Flow

-$18.81M

-80.6%

Operating Cash Flow

-$18.81M

-81.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FATEFate Therapeutics, Inc.
$2.51+6.36%
ALECAlector, Inc.
$1.62+6.58%
CRBPCorbus Pharmaceuticals Holdings, Inc.
$9.05+1.46%
MOLNMolecular Partners AG
$4.18+6.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About FBRX

What is the current price of Forte Biosciences?

Forte Biosciences is trading at $76.98 per share.

What is the 52-week range for Forte Biosciences?

Over the past 52 weeks, Forte Biosciences has traded between $9.10 and $77.20.

How much debt does Forte Biosciences have?

As of the most recent reporting period, Forte Biosciences reported total debt of $0.00.

How much cash does Forte Biosciences have on hand?

Forte Biosciences reported $58.22M in cash and cash equivalents in its most recent financial results.

What is Forte Biosciences’s dividend yield?

Forte Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services